Skip to main content

Coronavirus: Pharma giants granted coronavirus approvals but doubts remain on manufacturing a global vaccine

Julianna Tatelbaum




GS: GSK lab research 120119
A GSK lab in London.
Oli Scarff | Getty Images

There were several major developments over the last week with the medical community marking progress in all three critical areas: testing, treatments and vaccines.
Experts have welcomed positive data on potential treatments and progress on testing, but warn that vaccine timelines look ambitious and argue more thought is needed on manufacturing.  

Testing

On Sunday, Roche’s Covid-19 antibody test received FDA Emergency Use Authorization. The test is designed to help determine if a patient has been exposed to the virus and has developed antibodies against it. Roche will provide high double-digit millions of tests from this month.
Roche CEO Severin Schwan told CNBC on April 22 that, “Unlike with molecular tests which directly measure the virus, with antibody tests, the scaling is much easier from a technical point of view plus there is an enormous base of installed instruments and platforms out there.”

Treatments

After weeks of speculation and mixed messages from prematurely released data, Gilead’s experimental drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for Covid-19 on Friday. This will enable broader use of remdesivir to treat hospitalized patients with severe Covid-19 in the United States.
On April 30, the European Medicines Agency announced a “rolling” review of remdesivir, which enables the agency to assess data on the drug as it becomes available, speeding up the evaluation process and potentially paving the way for faster approval.
Separately, initial data on Kevzara, a rheumatoid arthritis drug co-developed by Regeneron and Sanofi seen as a potential treatment, delivered mixed results. It showed promise for treating the sickest patients but no benefit for less severe cases. As a result, the companies decided to stop testing the drug with those patients and are instead proceeding with a larger trial only in critical patients. Results are due in June.
JPMorgan’s U.S. biotechnology equity research team commented on Kevzara in a published note on Friday: “Although this might come as a relative disappointment to some — especially given the heightened sensitivities around Covid-19 — we continue to believe Regeneron may have a better shot treating this pandemic with its antibody cocktail.”

Vaccines

On the vaccine front, more manufacturing partnerships were announced last week, underlining the importance of discovering a vaccine that works but also ensuring there is enough to go around. Bank of America’s U.S. biopharmaceuticals equity research team hosted a biotech policy landscape call for clients last week which concluded that there needs to be some very serious thought on manufacturing.
Moderna announced a 10-year manufacturing agreement with Lonza that could result in the production of 1 billion doses per year. Goldman Sachs equity research said in a research note published May 1 that “based on Moderna’s vaccine portfolio data to date, we remain optimistic into the initial Covid-19 vaccine results, and view the Lonza collaboration as further supporting Moderna’s continued efforts to produce a Covid-19 vaccine to meet global demand.” The company says a phase three trial could begin as soon as the fall of 2020.
AstraZeneca and the University of Oxford announced last week an agreement on the global development and distribution of the university’s potential vaccine. The plan is to produce up to 100 million doses by the end of the year. The Oxford team is aiming to have the vaccine available by September.
Pascal Soriot, the chief executive officer of AstraZeneca, said in a press release: “This collaboration brings together the University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities.”
Prior to that announcement, India’s Serum Institute, the world’s biggest vaccine manufacturer, said it plans to produce up to 60 million doses of the potential vaccine by the end of the year.
The UBS health-care equity research team hosted a client call with an American infectious disease epidemiologist last week and said in a published note that the expert thinks highly of the scientific group at Oxford University. However, the expert was doubtful on the proposed timeline, considering the amount of data and follow-up time required to establish safety and efficacy of a vaccine.
Furthermore, the expert warned that even if a vaccine demonstrates safety and efficacy, there are significant additional challenges with manufacturing and distributing doses for the global population of nearly 8 billion.
Several other partnerships have already been announced including between Pfizer and BioNTech, and Sanofi and GlaxoSmithKline.
There are currently at least 89 vaccines for the coronavirus in development globally, according to the WHO. Experts have predicted that it will take between 12 and 18 months for a vaccine to be deemed safe for distribution to the market. 

Comments

Popular posts from this blog

Analysis | The Cybersecurity 202: How the shutdown could make it harder for the government to retain cybersecurity talent

By Joseph Marks 13-17 minutes THE KEY President Trump delivers an address about border security amid a partial government shutdown on Jan. 8. (Carolyn Kaster/AP) The partial government shutdown that's now in its 18th day is putting key cyber policy priorities on hold and leaving vital operations to a bare bones staff. But the far greater long-term danger may be the blow to government cyber defenders' morale, former officials warn. With the prospect of better pay and greater job security in the private sector, more government cyber operators are likely to decamp to industry, those former officials tell me, and the smartest cybersecurity graduates will look to industry rather than government to hone their skills. That’s especially dangerous, they say, considering the government’s struggle to recruit and retain skilled workers amid a nationwide shortage of cybersecurity talent. About 20 percent of staffers are furloughed at the De

Democrats call for investigation into Trump’s iPhone use after a report that China is listening:Analysis | The Daily 202 I The Washington Post.

washingtonpost.com By James Hohmann _________________________________________________________________________________ President Trump and Chinese President Xi Jinping visit the Great Hall of the People in Beijing last November. (Andrew Harnik/AP) With Breanne Deppisch and Joanie Greve THE BIG IDEA: If Democrats win the House in two weeks, it’s a safe bet that one of the oversight hearings they schedule for early next year would focus on President Trump’s use of unsecured cellphones. The matter would not likely be pursued with anywhere near the gusto that congressional Republicans investigated Hillary Clinton’s use of a private email server during her time as secretary of state. Leaders of the minority party have higher priorities . But Democratic lawmakers made clear Thursday morning that they will not ignore a New York Times report that Trump has refused to stop using iPhones in the White House, despite repeated warnings from U.S. intelligence offici

RTTNews: Morning Market Briefing.-Weekly Jobless Claims Edge Down To 444,000. May 13th 2010

Morning Market Briefing Thu May 13 09:01 2010   Commentary May 13, 2010 Stocks Poised For Lackluster Open Amid Mixed Market Sentiment - U.S. Commentary Stocks are on pace for a mixed start to Thursday's session, as a mostly upbeat jobs report continued to relieve the markets while some consternation regarding the European debt crisis remained on traders' minds. The major index futures are little changed, with the Dow futures down by 4 points. Full Article Economic News May 13, 2010 Weekly Jobless Claims Edge Down To 444,000 First-time claims for unemployment benefits showed another modest decrease in the week ended May 8th, according to a report released by the Labor Department on Thursday, although the number of claims exceeded estimates due to an upward revision to the previous week's data. Full Article May 13, 2010 Malaysia's Decade High Growth Triggers Policy Tightening Malaysia's economy grew at the fastest pace in a decade in